HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Pneumonia (Pneumonitis)

Inflammation of any part, segment or lobe, of the lung parenchyma.
Also Known As:
Pneumonitis; Lobar Pneumonia; Experimental Lung Inflammations; Inflammation, Experimental Lung; Inflammation, Lung; Inflammation, Pulmonary; Inflammations, Lung; Inflammations, Pulmonary; Lung Inflammation, Experimental; Lung Inflammations; Lung Inflammations, Experimental; Pneumonias; Pneumonitides; Pulmonary Inflammations; Experimental Lung Inflammation; Lung Inflammation; Pneumonia, Lobar; Pulmonary Inflammation
Networked: 26841 relevant articles (1715 outcomes, 2813 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Infection
2. Sepsis (Septicemia)
3. Human Influenza (Influenza)
4. Chronic Bronchitis
5. Urinary Tract Infections (Urinary Tract Infection)

Experts

1. van der Poll, Tom: 78 articles (10/2015 - 01/2002)
2. Kohno, Shigeru: 59 articles (06/2015 - 05/2002)
3. Torres, Antoni: 54 articles (01/2016 - 02/2002)
4. Florquin, Sandrine: 46 articles (01/2015 - 01/2002)
5. Yanagihara, Katsunori: 40 articles (06/2015 - 05/2002)
6. Marrie, Thomas J: 38 articles (02/2014 - 02/2002)
7. Welte, Tobias: 36 articles (10/2015 - 06/2005)
8. Kollef, Marin H: 36 articles (10/2015 - 03/2003)
9. Restrepo, Marcos I: 34 articles (10/2015 - 01/2005)
10. Torres, A: 34 articles (09/2015 - 01/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pneumonia:
1. Anti-Bacterial Agents (Antibiotics)IBA
2. Ofloxacin (Levofloxacin)FDA LinkGeneric
3. Amoxicillin (Wymox)FDA LinkGeneric
4. Penicillins (Penicillin)FDA Link
5. linezolid (Zyvox)FDA Link
6. Clarithromycin (Biaxin)FDA LinkGeneric
7. VancomycinFDA LinkGeneric
11/01/2011 - "A prospective cohort study was performed to determine the optimal dose of vancomycin to maintain a serum trough concentration of at least 15 to 20 mg/l and to assess the efficacy of this target vancomycin concentration in the treatment of methicillin-resistant Staphylococcus aureus pneumonia. "
09/01/2009 - "Due to the emergence of vancomycin-intermediate resistance at a fAUC24/MIC of < or = 210, exceeding this exposure breakpoint in ELF may help to guide optimal dosage regimens in the treatment of MRSA pneumonia."
01/01/2004 - "Clinical and pharmacokinetic information was used to determine the following: (i) whether steady-state 24-hour area under the concentration-time curve (AUC24) divided by the MIC (AUC24/MIC) values for vancomycin could be precisely calculated with a software program; (ii) whether the percentage of time vancomycin serum concentrations were above the MIC (%Time>MIC) was an important determinant of vancomycin response; (iii) whether the time to bacterial eradication differed as the AUC24/MIC value increased; (iv) whether the time to bacterial eradication for vancomycin differed compared with other antibacterials at the same AUC24/MIC value; and (v) whether a relationship existed between time to bacterial eradication and time to significant clinical improvement of pneumonia symptoms. "
09/01/2005 - "MRSA pneumonia: better outcome through continuous infusion of vancomycin?"
04/01/2011 - "The objective of this study is to assess the distribution of vancomycin minimum inhibitory concentrations (MICs) in methicillin-resistant Staphylococcus aureus (MRSA) isolates and evaluate the efficacy of vancomycin relative to vancomycin MICs in adult patients with MRSA nosocomial pneumonia. "
8. Erythromycin (Erycette)FDA LinkGeneric
9. Ceftazidime (Fortum)FDA LinkGeneric
10. Ciprofloxacin (Cipro)FDA LinkGeneric

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Artificial Respiration (Mechanical Ventilation)
04/01/2011 - "Current smokers also had significantly greater odds of pneumonia (odds ratio [OR], 2.09; 95% CI, 1.80-2.43), unplanned intubation (OR, 1.87; 95% CI, 1.58-2.21), and mechanical ventilation (OR, 1.53; 95% CI, 1.31-1.79). "
01/01/2006 - "There was a significant reduction in the incidence of nosocomial pneumonia (pooled odds ratio (OR) 0.38, 95% confidence interval (CI) 0.28 to 0.53), but no reduction in mortality (pooled OR 0.96, 95%CI 0.66 to 1.14), duration of mechanical ventilation (pooled standardized mean difference (SMD) -0.14 days, 95%CI, -0.29 to 0.02), duration of intensive care unit stay (pooled SMD -0.064 days, 95% CI, -0.21 to 0.086) or duration of hospital stay (pooled SMD 0.05 days, 95% CI -0.18 to 0.27). "
05/01/2005 - "Histologic examination showed increased recruitment of the dependent lung in groups 3 and 4, with significantly greater lung expansion index, than groups 1 and 2. PLV, with a single dose of higher viscosity and lower vapor pressure PFC, resulted in significantly improved gas exchange and lung mechanics with significant reduction in lung inflammation compared with conventional mechanical ventilation alone and PLV with lower viscosity and higher vapor pressure liquid. "
07/01/2004 - "Notable results were the greater requirement for mechanical ventilation in Legionella pneumonia and the good results obtained by home-based hospital care within current health care management."
08/01/2008 - "Systolic BP is superior to other haemodynamic predictors of 30 day mortality and need for mechanical ventilation and/or inotropic support in community acquired pneumonia. "
3. Transplants (Transplant)
4. Mechanical Ventilators (Ventilator)
5. Home Nursing (Nursing, Home)